As advised in our 7 June announcement of the trial results, Dr Barry Snow is presenting 81 week+ data on the safely and clinical effects of NTCELL in patients with Parkinson’s disease at the 20th International Congress of Parkinson’s Disease and Movement Disorders in Berlin. The presentation, in the form of a poster entitled “Safety and clinical effects of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease (PD): 81 to 130 weeks follow-up” takes place at 12 noon Berlin time today.

Dr Snow, Principal Investigator for the trial, said, “This data shows a striking and significant improvement in all measurements of Parkinson’s disease in the four patients. Everything we measured has improved.”

Dr Ken Taylor, CEO of LCT, said, “The results of this clinical trial are consistent with what LCT has found in pre-clinical studies. Moreover microarray analyses identified that several nerve growth factors and nerve protective agents are released from NTCELL and this may explain the improvement observed in all of the measurements of Parkinson’s disease.”

The poster is available to view here.

For further information: www.lctglobal.com

At the Company:Ken Taylor, +64 9 276 2690Chief ExecutiveMobile: +64 21 796 000ktaylor@lctglobal.comorMedia Contact:Botica Butler Raudon PartnersRachael Joel, +64 9 303 3862Mobile: +64 21 403 504rachaelj@botica.co.nz

Living Cell Technologies (ASX:LCT)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Living Cell Technologies Charts.
Living Cell Technologies (ASX:LCT)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Living Cell Technologies Charts.